Insulin Resistance in Type 1 Diabetes: Concepts and Implications for Therapy.
作者信息
Bloomgarden Zachary, Accili Domenico
机构信息
Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Medicine, Columbia University Vagelos College of Physicians & Surgeons, New York, New York, USA.
出版信息
J Diabetes. 2025 Jul;17(7):e70126. doi: 10.1111/1753-0407.70126.
Abstract
摘要
相似文献
1
Insulin Resistance in Type 1 Diabetes: Concepts and Implications for Therapy.
J Diabetes. 2025 Jul;17(7):e70126. doi: 10.1111/1753-0407.70126.
2
Zinc supplementation for the prevention of type 2 diabetes mellitus in adults with insulin resistance.
Cochrane Database Syst Rev. 2015 May 28;2015(5):CD005525. doi: 10.1002/14651858.CD005525.pub3.
3
Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.
Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD006691. doi: 10.1002/14651858.CD006691.pub2.
4
Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study.
Diabetologia. 2025 Feb 14. doi: 10.1007/s00125-025-06369-8.
5
Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial.
Diabetologia. 2025 Mar;68(3):676-687. doi: 10.1007/s00125-024-06327-w. Epub 2024 Dec 20.
6
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD009966. doi: 10.1002/14651858.CD009966.pub2.
7
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.
Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536.
8
Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity.
Diabetologia. 2025 Apr 30. doi: 10.1007/s00125-025-06429-z.
9
Low-frequency ultrasound reverses insulin resistance and diabetes-induced changes in the muscle transcriptome in aged mice.
Am J Physiol Endocrinol Metab. 2025 Jun 1;328(6):E899-E910. doi: 10.1152/ajpendo.00470.2024. Epub 2025 May 5.
10
A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version).
Diabetol Int. 2024 Jul 11;15(3):327-345. doi: 10.1007/s13340-024-00723-8. eCollection 2024 Jul.
本文引用的文献
1
Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study.
Diabetes Obes Metab. 2025 Mar;27(3):1591-1596. doi: 10.1111/dom.16149. Epub 2024 Dec 27.
2
GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes.
JAMA. 2024 Nov 19;332(19):1667-1669. doi: 10.1001/jama.2024.18581.
3
Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus.
Front Pharmacol. 2023 Mar 16;14:975880. doi: 10.3389/fphar.2023.975880. eCollection 2023.
4
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
J Clin Endocrinol Metab. 2023 Mar 10;108(4):920-930. doi: 10.1210/clinem/dgac618.
5
Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial.
J Pediatr Endocrinol Metab. 2022 Mar 7;35(4):505-510. doi: 10.1515/jpem-2021-0704. Print 2022 Apr 26.
6
Changes of insulin resistance status and development of complications in type 1 diabetes mellitus: Analysis of DCCT/EDIC study.
Diabetes Res Clin Pract. 2022 Feb;184:109211. doi: 10.1016/j.diabres.2022.109211. Epub 2022 Jan 20.
7
Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes.
Eur J Endocrinol. 2021 Nov 10;185(6):831-840. doi: 10.1530/EJE-21-0636.
8
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3842-53. doi: 10.1210/clinem/dgaa575.
9
Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study.
Diabetes Care. 2020 Oct;43(10):e139-e141. doi: 10.2337/dc20-0433. Epub 2020 Aug 13.
10
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Lancet Diabetes Endocrinol. 2019 Dec;7(12):949-958. doi: 10.1016/S2213-8587(19)30154-8. Epub 2019 Oct 1.
Zotero 插件